Adnkronos (Adnkronos) – “If I had to identify the main obstacle to the competitiveness of the pharmaceutical sector in Italy today, one of the most characteristic elements is certainly that linked to payback, a system that has been in place for quite some time, but which today needs to be reformed, revised, also to allow innovation to be an integral part of the availability of therapeutic options for all citizens.
So it's certainly one of the elements we need to work on, and it's also one of the signals that the new budget law has begun to lay the groundwork for, so we're confident we can continue working in this direction." This was stated by Paolo Siviero, Director of Access and Regulatory Strategies at Farmindustria, speaking at the event "The Future of Pharmaceutical Legislation: A Systemic Vision," organized by Nuove Reti in Rome.
"The Consolidated Law offers a great opportunity," he explains, "to revise certain regulations, primarily the payback framework and the overall governance structure of the pharmaceutical system. In this regard, we need to move toward a stronger connection with the health outcomes produced. Therefore, a synergistic relationship between the benefits for the patient and the benefits for the system," he notes. "This is one of the elements we can work on, one on which the Consolidated Law can lay the foundation for future work, also thanks to the modernization of the entire data collection and use within the system."
And it is precisely on modernization and the innovation it brings that Siviero focuses: "Innovation is a key component for the health of all citizens, and it is also a key component for a manufacturing system like Italy's, which is undoubtedly one of the leading providers in Europe. We must ensure that it reaches patients and the system as a whole." For this to happen, on the one hand, "a synergy between the health outcomes produced and the benefits for the system as a whole is needed, and on the other, the ability to remain an attractive system, including in terms of clinical trials and the system's ability to embrace innovation," he concludes.
saving
webinfo@adnkronos.com (Web Info)